Heart Failure with Reduced versus Preserved Ejection Fraction: Molecular Mechanisms, Immunologic Pathways, Current Therapies, and Future Directions.

Kim E, Agrawal DK

Open source

DOI
10.26502/aimr.0254
Published
2026 Sep
Container
Archives of internal medicine research
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.26502/aimr.0254,
  title = {Heart Failure with Reduced versus Preserved Ejection Fraction: Molecular Mechanisms, Immunologic Pathways, Current Therapies, and Future Directions.},
  author = {Kim E and Agrawal DK},
  year = {2026},
  journal = {Archives of internal medicine research},
  doi = {10.26502/aimr.0254},
  url = {https://doi.org/10.26502/aimr.0254}
}

RIS

TY  - JOUR
TI  - Heart Failure with Reduced versus Preserved Ejection Fraction: Molecular Mechanisms, Immunologic Pathways, Current Therapies, and Future Directions.
AU  - Kim E
AU  - Agrawal DK
PY  - 2026
JO  - Archives of internal medicine research
DO  - 10.26502/aimr.0254
UR  - https://doi.org/10.26502/aimr.0254
ER  - 

APA

E, K., & DK, A. (2026). Heart Failure with Reduced versus Preserved Ejection Fraction: Molecular Mechanisms, Immunologic Pathways, Current Therapies, and Future Directions.. Archives of internal medicine research. https://doi.org/10.26502/aimr.0254

Source records